NEW YORK, Jan. 10, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on OPHT, TRVN, PTCT, and HALO which can be accessed for free by signing up to www.wallstequities.com/registration. This morning's focus is shifted on the Biotech space, which is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money. Pre-market, WallStEquities.com scans the following companies: Ophthotech Corp. (NASDAQ: OPHT), Trevena Inc. (NASDAQ: TRVN), PTC Therapeutics Inc. (NASDAQ: PTCT), and Halozyme Therapeutics Inc. (NASDAQ: HALO). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Ophthotech
Shares in New York headquartered Ophthotech Corp. saw a decline of 4.61%, ending Tuesday's trading session at $2.90. The stock recorded a trading volume of 368,667 shares. The Company's shares have gained 12.40% over the last three months. The stock is trading 4.21% above its 200-day moving average. Moreover, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have a Relative Strength Index (RSI) of 43.91.
On January 02nd, 2018, Ophthotech announced that Glenn P. Sblendorio, CEO and President, will present an overview of the Company at the 36th Annual J.P. Morgan Healthcare Conference on January 11th, 2018, at 11:00 a.m. ET in San Francisco. A live webcast of the presentation will be available on the Company's website. Get the full research report on OPHT for free by clicking below at:
www.wallstequities.com/registration/?symbol=OPHT
Trevena
King of Prussia, Pennsylvania headquartered Trevena Inc.'s stock declined slightly by 0.57%, closing the day at $1.75 with a total trading volume of 733,803 shares. The Company's shares have surged 22.38% in the past month. The stock is trading 7.72% above its 50-day moving average. Additionally, shares of Trevena, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 53.00.
On January 02nd, 2018, Trevena announced that the US FDA has accepted its New Drug Application (NDA) for OLINVOTM (oliceridine) Injection. The Company expects that the PDUFA date for the NDA will be in Q4 2018. OLINVO is an investigational product for the management of moderate to severe acute pain. It is the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer associated adverse effects. Access the free research report on TRVN now by signing up at:
www.wallstequities.com/registration/?symbol=TRVN
PTC Therapeutics
On Tuesday, shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. recorded a trading volume of 1.59 million shares, which was higher than their three months average volume of 954,760 shares. The stock ended the day 2.12% higher at $20.67. The Company's shares have advanced 23.40% in the past month, 12.46% in the previous three months, and 59.61% over the past year. The stock is trading above its 50-day and 200-day moving averages by 24.56% and 25.93%, respectively. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 84.47.
On January 03rd, 2018, PTC Therapeutics announced that it will present a Company overview at the upcoming 36th Annual JP Morgan Healthcare Conference on January 10th, 2018, at 2:30 p.m. PT. The presentation will be webcast live under the investor relations section of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on PTCT at:
www.wallstequities.com/registration/?symbol=PTCT
Halozyme Therapeutics
San Diego, California headquartered Halozyme Therapeutics Inc.'s stock declined slightly by 0.32%, finishing yesterday's session at $18.66. A total volume of 1.37 million shares was traded, which was above their three months average volume of 1.22 million shares. The Company's shares have advanced 11.40% in the previous three months and 31.04% over the past year. The stock is trading above its 200-day moving average by 23.00%. Additionally, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes and other drug candidates in the US, Switzerland, and internationally, have an RSI of 38.60. Aspiring Member, please take a moment to register below for your free research report on HALO at:
www.wallstequities.com/registration/?symbol=HALO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----ophthotech-trevena-ptc-therapeutics-and-halozyme-therapeutics-300580612.html
SOURCE Wall St. Equities
